These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34770047)

  • 1. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
    Blum K; Bowirrat A; Braverman ER; Baron D; Cadet JL; Kazmi S; Elman I; Thanos PK; Badgaiyan RD; Downs WB; Bagchi D; Llanos-Gomez L; Gold MS
    Int J Environ Res Public Health; 2021 Nov; 18(21):. PubMed ID: 34770047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
    Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M
    Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
    Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
    Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
    Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
    J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
    Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
    CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
    Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
    J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
    Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
    Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?
    Blum K; McLaughlin T; Bowirrat A; Modestino EJ; Baron D; Gomez LL; Ceccanti M; Braverman ER; Thanos PK; Cadet JL; Elman I; Badgaiyan RD; Jalali R; Green R; Simpatico TA; Gupta A; Gold MS
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
    Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
    Gold MS; Baron D; Bowirrat A; Blum K
    J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
    Blum K; Baron D; McLaughlin T; Gold MS
    J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry.
    Blum K; Ashford JW; Kateb B; Sipple D; Braverman E; Dennen CA; Baron D; Badgaiyan R; Elman I; Cadet JL; Thanos PK; Hanna C; Bowirrat A; Modestino EJ; Yamamoto V; Gupta A; McLaughlin T; Makale M; Gold MS
    J Neurol Sci; 2023 Oct; 453():120809. PubMed ID: 37774561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reward deficiency syndrome: genetic aspects of behavioral disorders.
    Comings DE; Blum K
    Prog Brain Res; 2000; 126():325-41. PubMed ID: 11105655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term.
    Blum K; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Thanos PK; Demetrovics Z; Febo M
    J Reward Defic Syndr Addict Sci; 2016; 2(1):14-21. PubMed ID: 28317038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
    Blum K; Modestino EJ; Neary J; Gondré-Lewis MC; Siwicki D; Moran M; Hauser M; Braverman ER; Baron D; Steinberg B; Laughlin TM; Badgaiyan RD
    Biomed J Sci Tech Res; 2018 Jan; 2(2):1-4. PubMed ID: 30370423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
    Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
    Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword?
    Blum K; Cadet JL; Baron D; Badgaiyan RD; Brewer R; Modestino EJ; Gold MS
    Subst Use Misuse; 2020; 55(14):2438-2442. PubMed ID: 32957797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
    Madigan MA; Gupta A; Bowirrat A; Baron D; Badgaiyan RD; Elman I; Dennen CA; Braverman ER; Gold MS; Blum K
    Int J Environ Res Public Health; 2022 May; 19(11):. PubMed ID: 35681980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Death by Opioids: Are there non-addictive scientific solutions?
    Downs BW; Blum K; Baron D; Bowirrat A; Lott L; Brewer R; Boyett B; Siwicki D; Roy AK; Podesta A; Badgaiyan S; Hajela R; Fried L; Badgaiyan RD
    J Syst Integr Neurosci; 2019 Jun; 5():. PubMed ID: 31824737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
    Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
    J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.